Monobodies as possible next-generation protein therapeutics - a perspective.


Over the past two decades, hundreds of new somatic mutations have been identified in tumours, and a few dozen novel cancer therapeutics that selectively target these mutated oncoproteins have entered clinical practice. This development has resulted in clinical breakthroughs for a few tumour types, but more commonly patients' overall survival has not… (More)
DOI: 10.4414/smw.2017.14545


  • Presentations referencing similar topics